A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
CG Oncology, Inc.
CGON
$5.4B
Mkt Cap
$69.32
-2.53%
CG Oncology, Inc. (CGON) has a 5-year average return on invested capital (ROIC) of -22.4%. This is below average and may indicate limited pricing power.
CG Oncology, Inc. (CGON) has a market capitalization of $5.4B. It is classified as a mid-cap stock.
CG Oncology, Inc. (CGON) does not currently pay a regular dividend.
CG Oncology, Inc. (CGON) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
CG Oncology, Inc. (CGON) generated $-132 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
CG Oncology, Inc. (CGON) reported earnings per share (EPS) of $-2.08 in its most recent fiscal year.
The Ledger Terminal provides 3 years of financial data for CG Oncology, Inc. (CGON), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
RISK FACTORS SUMMARY The risks described in the section titled “Risk Factors” in Part I of this Annual Report could impact our ability to realize the full benefits of our strengths or execute all or part of our strategy. Some of the more significant risks described in “Risk Factors” include the following: Risks Related to the Development and Regulatory Approval of Our Product Candidates •We currently depend entirely on the success of cretostimogene, which is our only product candidate. If we are unable to advance cretostimogene in clinical development, obtain regulatory approval and ultimately commercialize cretostimogene, or experience significant delays in doing so, our business will be materially harmed. •Cretostimogene is based on a novel approach to the treatment of cancer, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval, if at all.
| Metric | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | 0 | - | - | - |
| Net Income | -161M | -161M | -88M | -68M |
| EPS | $-2.08 | $-2.08 | $-1.41 | $-15.65 |
| Free Cash Flow | -132M | -132M | -79M | -46M |
| ROIC | - | -24.1% | -15.2% | -27.8% |
| Gross Margin | - | - | - | - |
| Debt/Equity | 0.00 | - | - | -0.00 |
| Dividends/Share | $0.00 | - | - | - |
| Operating Income | -191M | -191M | -115M | -55M |
| Operating Margin | 0.0% | - | - | - |
| ROE | 0.0% | - | - | - |
| Shares Outstanding | 77M | 77M | 62M | 76M |
| Metric | 2023 | |||
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A |
| R&D | 46M | 82M | 117M | 117M |
| SG&A | 9.9M | 34M | 74M | 74M |
| EBIT | -55M | -115M | -191M | -191M |
| Op. Margin | N/A | N/A | N/A | 0.0% |
| Net Income | -68M | -88M | -161M | -161M |
| Net Margin | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||
| ROIC | -27.8% | -15.2% | -24.1% | N/A |
| ROE | N/A | N/A | N/A | 0.0% |
| ROA | -34.0% | -11.7% | -20.8% | -20.3% |
| Cash Flow | ||||
| Op. Cash Flow | -46M | -79M | -132M | -132M |
| Free Cash Flow | -46M | -79M | -132M | -132M |
| Owner Earnings | -47M | -90M | -160M | -160M |
| CapEx | 0 | 234K | 134K | 134K |
| Maint. CapEx | 17K | 32K | 1.4M | 1.4M |
| Growth CapEx | N/A | 202K | 0 | 0 |
| D&A | 17K | 32K | 1.4M | 1.4M |
| CapEx/OCF | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 1.5M | 11M | 27M | 27M |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||
| Net Debt | -187M | -742M | -735M | -25M |
| Cash & Equiv. | 8.3M | 257M | 32M | 32M |
| Long-Term Debt | N/A | 0 | 3.0M | 3.0M |
| Debt/Equity | -0.00 | N/A | N/A | 0.00 |
| Interest Coverage | -147.5 | N/A | -1852.2 | -1852.2 |
| Equity | -123M | N/A | N/A | 0 |
| Total Assets | 199M | 755M | 792M | 792M |
| Total Liabilities | 15M | N/A | N/A | N/A |
| Intangibles | N/A | 0 | 575K | 575K |
| Retained Earnings | -130M | -218M | -379M | -379M |
| Working Capital | 180M | 733M | 729M | 729M |
| Current Assets | 194M | 754M | 759M | 759M |
| Current Liabilities | 14M | 21M | 31M | 31M |
| Per Share Data | ||||
| EPS | -15.65 | -1.41 | -2.08 | -2.08 |
| Owner EPS | -0.62 | -1.44 | -2.07 | -2.07 |
| Book Value | -1.62 | N/A | N/A | 0.00 |
| Cash Flow/Share | -0.60 | -1.26 | -1.71 | -2.06 |
| Dividends/Share | N/A | N/A | N/A | 0.00 |
| Shares Out. | 76.2M | 62.4M | 77.4M | 77.4M |
| Valuation | ||||
| P/E Ratio | N/A | N/A | N/A | -33.3 |
| P/FCF | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | -4.2% | -4.3% | -2.5% |
| Market Cap | N/A | 1.9B | 3.1B | 5.4B |
| Avg. Price | N/A | 35.89 | 30.63 | 69.32 |
| Year-End Price | N/A | 30.04 | 39.84 | 69.32 |
CG Oncology, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.